WO2003080075A1 - Ameliorant pour le traitement chimique du cancer - Google Patents
Ameliorant pour le traitement chimique du cancer Download PDFInfo
- Publication number
- WO2003080075A1 WO2003080075A1 PCT/JP2002/002914 JP0202914W WO03080075A1 WO 2003080075 A1 WO2003080075 A1 WO 2003080075A1 JP 0202914 W JP0202914 W JP 0202914W WO 03080075 A1 WO03080075 A1 WO 03080075A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cancer
- agent
- group
- cancer chemotherapy
- chemotherapeutic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
- C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/04—Heterocyclic radicals containing only oxygen as ring hetero atoms
Definitions
- the present invention relates to a novel agent for improving cancer chemotherapy. Specifically, it is a cancer chemotherapeutic ameliorating agent containing a water-soluble mouth mannose glycoside as an active ingredient.
- Cancer has been the leading cause of death in Japan since 1981, and the number of patients is increasing year by year.
- basic research and clinical research on cancer treatment have progressed on a global level in the last 10 years or so, and advances in cancer diagnostic technology have enabled early detection and treatment of cancer.
- cancer chemotherapy is a method of treating malignant tumors by administering anticancer drugs.However, since there is no essential difference in the effect on cancer cells and normal cells, the stronger the effect, the stronger the side effects.
- cisplatin has serious side effects such as renal dysfunction, nausea, vomiting, neuropathy, leukopenia, thrombocytopenia, and bone marrow disorders such as anemia.
- the occurrence of such side effects associated with cancer chemotherapy often leads to a situation in which the dose of the anticancer drug must be limited or the treatment must be stopped.
- suppression of side effects has a significant effect on the survival of patients. Therefore, when performing cancer chemotherapy, it is extremely important to suppress side effects without suppressing the therapeutic effects of anticancer drugs.
- Drugs that suppress the side effects of chemotherapy include nausea and vomiting.
- 5-HT 3 receptor antagonists such as lanisetron and ondansetron
- bone marrow function activators such as filgrastim and lenograstim for leukopenia and the like.
- cancer chemotherapy there is a further demand for the development of a novel cancer chemotherapy improving agent that enhances the anticancer action of anticancer drugs and suppresses various side effects.
- the chromanol glycoside used in the present invention is a known compound (Japanese Patent Application Laid-Open Nos. 7-118887, 9-246988, and Japanese Patent Application Laid-Open No. No. 1 2291).
- the chromanyl glycoside is obtained by substituting the 2-position phytyl group of chroman ⁇ of the tocopherol, which is a typical biminemin E, with an alcohol and further linking a sugar, and has a high water solubility. Has excellent properties and excellent antioxidant action.
- the chromanol glycoside is used as the above-mentioned cancer chemotherapeutic improving agent.
- the present invention has been made in view of the above-mentioned problems of the related art.
- the objective is to provide a novel cancer chemotherapeutic ameliorating agent that acts safely and effectively at a small dose and has an excellent inhibitory effect on various side effects associated with cancer chemotherapy. .
- Another object of the present invention is to provide a novel cancer chemotherapeutic ameliorating agent capable of enhancing the anticancer effect of an anticancer drug in cancer chemotherapeutics. Disclosure of the invention
- the present inventors have conducted intensive studies on drugs that suppress the side effects of cancer chemotherapy. As a result, the chromanol glycoside not only enhances the anticancer action of anticancer drugs, but also extremely effectively The inventors have found that various side effects associated with chemotherapy are suppressed, and completed the present invention.
- R 5 represents a hydrogen atom, a lower alkyl group or a lower acyl group
- X represents Represents a monosaccharide residue or an oligosaccharide residue in which the hydrogen atom of the hydroxyl group in the sugar residue may be substituted with a lower alkyl group or a lower acyl group
- n is an integer of 0 to 6
- m is Which is an integer of 1 to 6).
- the present invention is also the above-mentioned cancer chemotherapeutic ameliorating agent, which is a side effect suppressing agent.
- the present invention is also the above-mentioned cancer chemotherapeutic ameliorating agent, which is an anticancer action enhancer.
- the present invention also provides the cancer chemotherapy ameliorating agent, wherein the cancer chemotherapy is a cytotoxic anticancer drug treatment.
- the present invention also provides the cancer chemotherapy ameliorating agent, wherein the cytotoxic anticancer agent is an alkylating agent, an antitumor plant component preparation, an antitumor antibiotic preparation or a DNA chelating agent.
- the cytotoxic anticancer agent is an alkylating agent, an antitumor plant component preparation, an antitumor antibiotic preparation or a DNA chelating agent.
- the present invention also provides the cancer chemotherapy ameliorating agent, wherein the cytotoxic anticancer agent is cisplatin, cyclophosphamide or doxorubicin hydrochloride.
- the present invention also provides the cancer chemotherapy ameliorating agent, wherein the chromanyl glycoside is 2-(-D-glucovilanosyl) methyl-1,2,5,7,8-tetramethylchroman-6-ol. .
- the present invention is also the above agent for improving cancer chemotherapy, which is an aqueous preparation.
- the cancer chemotherapeutic ameliorating agent of the present invention is characterized by comprising a chromanol glycoside represented by the general formula (1) as an active ingredient.
- the lower alkyl group of R 1 R 2 , R 3 , R 4 and R 5 is preferably a lower alkyl group having 1 to 8, preferably 1 to 6 carbon atoms.
- a methyl group or an ethyl group is preferred.
- a lower acetyl group having 1 to 8 carbon atoms, preferably 1 to 6 carbon atoms is preferable, for example, formyl group, acetyl group, propionyl group, butyryl group, isobutyryl group, A valeryl group, an isovaleryl group, a bivaloyl group, a hexanoyl group, a heptanoyl group, an oxanoyl group and the like.
- an acetyl group, a propionyl group or a butyryl group is preferred.
- Examples of the monosaccharide residue of X include glucose, galactose, fucose, xylose, mannose, rhamnose, fructos, arabinose, lyxose, ribose, arose, altrose, idose, and evening rose. And sugar residues such as deoxyribose, 2-deoxyribose, quinobiose and avequose.
- Examples of the oligosaccharide residue of X include those in which 2 to 4 of the above monosaccharides are bonded, for example, sugar residues of maltose, lactose, cellobiose, rafinoose, xylobiose, and sucrose.
- the hydrogen atom of the hydroxyl group in the sugar residue of X is a lower alkyl group, preferably a lower alkyl group having 1 to 8 carbon atoms, or a lower acyl group, preferably a lower acyl group having 1 to 10 carbon atoms. May be substituted with a group.
- n is 0-6, good Preferably, it is an integer of 1-4, and m is an integer of 1-6, preferably 1-3.
- chromanyl glycoside represented by the general formula (1) examples include 2- (1-D-glucopyranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol, (? — D—galactobilanosyl) methyl-1,2,5,7,8—tetramethylchroman-1-ol, 2-( ⁇ L-fucopyranosyl) methyl-1,2,5,7,8—tetramethylchroman-6 —Ol, 2— (Hi-L-rhamnoviranosyl) methyl-2,5,7,8-tetramethylchroman-6-ol, 2-(?
- the chromanol glycoside used in the present invention can be produced, for example, by the methods described in JP-A-7-118287, JP-A-9-249688, and JP-A-11-129129 by the following method. Equation (2):
- the 2-substituted alcohol represented by the general formula (2) (hereinafter, simply referred to as “2-substituted alcohol”) used as a raw material in the above reaction is a known substance, for example, Japanese Patent Publication No. 43755/1991. It can be obtained by the method disclosed in Japanese Patent Publication No. 49-135.
- a 2-substituted alcohol in which R 1 R 2 , R 3 and R 4 are a methyl group, R 5 is a hydrogen atom, and n is 1 is a chromato ring of 1-tocopherol 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid (trade name: Trolox) having a structure in which the 2-position phytyl group is substituted with a carboxyl group
- the compound can be easily obtained by heating and refluxing in a gelatin solution in the presence of lithium aluminum chloride.
- Chromanol glycosides used in the present invention include those obtained by protecting the hydroxyl group at the 6-position of the 2-substituted alcohol with a protecting group by the method described in Japanese Patent Application No. 10-75599. Can also be produced by introducing a leaving group at the 1-position and subjecting a sugar derivative in which another hydroxyl group is protected with a protecting group to a condensation reaction.
- the chromanol glycoside according to the present invention is a water-soluble bimin E having lipophilicity. Therefore, unlike the conventional water-insoluble or poorly-soluble vitamin E derivatives, the chromanol glycosides according to the present invention maintain lipophilicity even when used in water, so that they penetrate cell membranes, In addition, it can enter the cells and not only enhances the therapeutic effect of anticancer drugs, but also effectively suppresses various side effects associated with cancer chemotherapy. In addition, the chromanyl glycoside obtained by the above reaction has markedly improved thermal stability and pH stability as compared with tocopherol, trolox or 2-substituted alcohol.
- the cancer chemotherapeutic ameliorating agent of the present invention can be used as an anticancer effect enhancer for enhancing the anticancer effect of an anticancer agent in cancer chemotherapeutic treatment and a side effect inhibitor for suppressing side effects associated with cancer chemotherapeutic treatment. .
- Examples of the cancer disease according to the present invention include brain tumor, head and neck cancer, stomach cancer, colon cancer, liver cancer, biliary tract cancer, Teng cancer, lung cancer, breast cancer, uterine cancer, ovarian cancer, prostate cancer, bladder cancer, bone, soft tissue tumor, and leukemia. And the like.
- the cancer chemotherapy in the present invention is a cancer treatment performed by administering an anticancer agent.
- the anticancer agent include an alkylating agent, an antitumor plant component preparation, an antitumor antibiotic preparation, and a DNA chelating agent. (Platinum compounds) and the like.
- the alkylating agent include cyclophosphamide, imidazole carboxamide, nitrazine dihydrochloride, chloroethylamine compounds such as dimethyl N-oxide, melphalan, and diphosphamide, carbocon, and triethylenethiophosphamide.
- Aziridine (ethyleneimine) compounds such as busulfan and improsulfan tosylate, epoxide compounds such as mitopronitol, ditrosourine compounds such as dimustine and ranimustine, estramustine sodium phosphate Pum and the like.
- antitumor plant component preparations include bintoal force preparations such as vincristine sulfate, vinplastin sulfate, and vindesine sulfate, podophyrin preparations such as etoposide, and irinotecan hydrochloride.
- Antineoplastic antibiotics include doxorubicin hydrochloride (adriamycin), idarubicin hydrochloride, daunorubicin hydrochloride, aclarubicin hydrochloride, epilubicin hydrochloride, anthracyclines such as pralubicin hydrochloride, pleomycins such as bleomycin and peptomycin sulfate, and the like.
- examples include mitomycins such as mitomycin C, actinomycins such as actinomycin D, polypeptides such as dinostin cinnamoma, neocartinosinotin and the like.
- DNA chelating agent examples include cisplatin, carboplatin, nedaplatin and the like.
- Other anticancer agents include sopoxane, tretinoin, pentosuxin, L-asparaginase, flutamide, porfimer sodium, huadrozol hydrochloride, procarpazine hydrochloride, asegratone, mitoxantrone hydrochloride and the like.
- the side effects of cancer treatment to which the agent for improving cancer chemotherapeutics of the present invention can be applied include myelopathy such as leukopenia, granulocytopenia, lymphopenia, thrombocytopenia, and erythrocytopenia which occur with the above cancer treatment.
- Blood disorders such as decreased plasma fibrinogen, nausea, vomiting, anorexia, severe stomach, digestive disorders such as diarrhea, constipation, stomatitis, esophagitis, lung disorders such as chronic pneumonia, pulmonary fibrosis, horns Skin disorders such as hyperplasia, hyperplasia, pigmentation, hair loss, rash, nail changes, paresthesia, loss of deep reflex, nerve paralysis, hearing impairment, speech disorders, disorientation, psychiatric symptoms, cerebellar ataxia, somnolence Nervous system disorders such as coma, dizziness, urinary frequency, and fecal frequency, pituitary gland disorders, adrenal disorders, endocrine disorders such as hyperglycemia and hypoglycemia, decreased libido, decreased sperm, gynecomastia Genital disorders, myocardial disorders Arrhythmia, hypotension, tachycardia, cardiac failure, etc. cardiovascular disorders, liver disorders, Teng disorders, renal disorders, ⁇ ⁇ disorders, hyperuri
- the cancer chemotherapeutic ameliorating agent of the present invention comprises a composition comprising the chromanol glycoside alone, or a composition obtained by mixing the chromanol glycoside with a pharmaceutically acceptable carrier, or dissolving or suspending in a pharmaceutically acceptable solvent. It is administered to patients orally or parenterally before, during, or after chemotherapy.
- the chromanol glycoside may be used alone or as an appropriate additive such as lactose, sucrose, mannitol, corn starch, synthetic or natural gum, crystalline cellulose, etc.
- Solid preparations such as tablets, powders (powder), pills, and granules can be prepared by appropriately mixing with diluents and the like.
- Capsules may be prepared using hard or soft gelatin capsules. These solid preparations are provided with an enteric coating using a coating base such as hydroxypropyl methylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, methacrylate copolymer, etc. Is also good. Further, the chromanyl glycoside is dissolved in a commonly used inert diluent such as purified water or physiological saline, and if necessary, a wetting agent, an emulsifier, a dispersing aid, Liquid preparations such as syrups and elixirs can be prepared by the appropriate addition of surfactants, sweeteners, flavors and fragrances.
- a coating base such as hydroxypropyl methylcellulose phthalate, hydroxypropylmethylcellulose acetate succinate, cellulose acetate phthalate, methacrylate copolymer, etc. Is also good.
- the chromanyl glycoside is
- the chromanol glycoside may be purified water, an appropriate buffer such as a phosphate buffer, physiological saline, Ringer's solution, or the like.
- Physiological saline solution such as Locke's solution, sterile aqueous solution, non-aqueous solution, suspension, ribosome or emulsion suitably combined with ethanol, glycerin and commonly used surfactants, preferably as sterile aqueous solution for injection It is administered intravenously, subcutaneously or intramuscularly.
- the liquid preparation preferably has a physiological pH, preferably in the range of 6 to 8.
- the cancer chemotherapeutic ameliorating agent of the present invention is used for liquid preparations such as lotions, suspensions, and emulsions, semisolid preparations such as gels, creams, and ointments, powders, powders, or dissolved and used at the time of application. Transdermally at the target site and surrounding area as a solid preparation such as granules May be given. In addition, it can be administered as a suppository using a pellet or as a suppository base.
- the preferred formulation and dosage form are selected by the attending physician.
- the concentration of the chromanol glycoside contained in the cancer chemotherapeutic agent of the present invention varies depending on the administration form, the type and severity of the disease, the intended dose, and the like. Is 0.1 to 100% by mass, preferably 1 to 90% by mass, based on the total mass of the compound. In particular, when the formulation of the present invention is administered orally, it is 1 to 100% by mass, preferably 5 to 90% by mass based on the total mass of the raw material. It is preferably 0.1 to 90% by volume, preferably 1 to 80% by volume, based on the total volume of the raw material.
- the concentration of the chromanol glycoside exceeds the upper limit, the inhibitory effect corresponding to the excessive dose cannot be obtained, and if the concentration is less than the lower limit, the inhibitory effect cannot be sufficiently expected, and neither is preferable. .
- the dose of the cancer chemotherapeutic ameliorating agent of the present invention varies depending on the patient's age, weight and condition, intended administration form and method, therapeutic effect, treatment period, etc., and the exact amount is determined by a physician. However, the dose is usually in the range of 0.01 to 200 mg / kg body weight in each case, in both oral and parenteral administration, in terms of the chromanol glycoside.
- the anticancer effect enhancing effect and side effect suppressing effect of the cancer chemotherapeutic agent of the present invention in cancer chemotherapeutic treatment were confirmed by the following pharmacological tests.
- chromanol glycoside 2- (hi-D-glucopyranosyl) methyl-1-2 represented by the following formula (3) produced by the method described in Example 1 of JP-A-7-118287 , 5,7,8-Tetramethylchroman-1-ol (TMG) was used.
- P388 leukemia cells (6 x 10 6 ) were administered intraperitoneally to 80 mice (8 per group, body weight 20-22 g) of 8-9 week old females, and the next day, cisplatin (CDDP) and A predetermined amount of T.MG was dissolved in 0.2 ml of physiological saline and administered intraperitoneally. Table 1 shows the results of measuring the survival rate 60 days after the administration of CDDP and TMG.
- P388 leukemia cells 6 ⁇ 10 6 cells were intraperitoneally administered to 8 to 9-week-old female mice (80 mice per group, weighing 20 to 22 g), and the next day (day 1) 36 Omg / kg cyclophosphamide (CPA) and 0.01 m gZkg of TMG was administered intraperitoneally. Thereafter, CPA (36 Omg / kg) was administered daily on days 3, 5, and 7, and TMG (0.0 lmg / kg) was administered daily from days 2 to 9. Table 2 shows the results of measuring the survival rate 60 days after the administration of CPA and TMG.
- mice Females aged 8 to 9 weeks: 61) P388 leukemia cells ( 6 ⁇ 10 6 cells) were intraperitoneally administered to mice (8 per group, body weight 20 to 22 g), and the following day (day 1) Adriamycin (ADM) at 16 mg / kg and a predetermined amount of TMG were administered intraperitoneally. Thereafter, ADM (16 mgZkg) was administered simultaneously on days 3, 5, and 7, and TMG (the predetermined amount) was administered simultaneously from day 2 to day 7. Table 3 shows the results of measuring the survival rate 7 days after ADM and TMG administration. Table 3
- a lethal dose of 16 mg / kg of CDDP was administered intraperitoneally to 10 8-week-old BDF mice (22 to 25 g) as a control group.
- the group that received 0.01 mg / kg of TMG at the same time as CDDP was designated as test group 1, and the group that was administered with 1.0 mg Zkg was designated as test group 2.
- Table 4 shows the results of measuring the daily changes in the survival rates of the control group and the test group.
- mice 5 mg of 8-week-old BDF mice were intraperitoneally administered with 2 mg / kg of CDDP once a day for 10 days to be used as a control group.
- Table 5 shows the results of the daily changes in the white blood cell count in the blood of the control group and the test group.
- a lethal dose of 1 mg of SDP was administered intraperitoneally to 50-week-old female mice of 8 to 9 weeks (8 mice / group, body weight: 20 to 22 g).
- Table 6 shows the results of examining the mortality 10 days after the administration of / kg.
- mice Females aged 8 to 9 weeks: P388 leukemia cells ( 6 ⁇ 10 6 ) were administered intraperitoneally to BDF mice (8 mice / group, body weight: 20 to 22 g). From the next day, ADM at 16 mg / kg was administered once daily for 9 days to serve as a control group. In addition, a group administered with 0.1 rngZkg of TMG once daily for 9 days at the same time as ADM was set as a test group.
- Table 7 shows the results of examining daily changes in body weight of the control group and the test group.
- a powder was obtained by mixing 100 g of TMG, 800 g of lactose and 100 g of corn starch in a blender.
- TMG 100 g
- lactose 110 g
- corn starch 58 g
- magnesium stearate 2 g
- a lotion was obtained by mixing and dissolving 3 g of TMG 1 s ethanol, 0.2 g of hydroxyethyl cellulose and 0.1 g of methyl parahydroxybenzoate in 100 ml of purified water.
- the cancer chemotherapeutic ameliorating agent of the present invention contains a water-soluble chromanyl glycoside as an active ingredient, and when used in combination, enhances the anticancer effect of cancer chemotherapeutic treatment. At the same time, it extremely effectively suppresses serious side effects that occur with cancer chemotherapy. As a result, cancer chemotherapy can be continued while maintaining the required dose of anticancer drug, maximizing the efficacy of cancer chemotherapy, and reducing the physical burden on patients Can be.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE60238874T DE60238874D1 (de) | 2002-03-26 | 2002-03-26 | Chromanol glucoside zur verbesserung der chemischen krebsbehandlung |
EP02707164A EP1488796B1 (en) | 2002-03-26 | 2002-03-26 | Chromanol glucosides for ameliorating cancer chemotherapy |
AT02707164T ATE493993T1 (de) | 2002-03-26 | 2002-03-26 | Chromanol glucoside zur verbesserung der chemischen krebsbehandlung |
PCT/JP2002/002914 WO2003080075A1 (fr) | 2002-03-26 | 2002-03-26 | Ameliorant pour le traitement chimique du cancer |
US10/507,760 US7462601B2 (en) | 2002-03-26 | 2002-03-26 | Ameliorant for chemical treatment of cancer |
EA200400968A EA009082B1 (ru) | 2002-03-26 | 2002-03-26 | Агент для улучшения химиотерапии рака |
JP2003577901A JP4509574B2 (ja) | 2002-03-26 | 2002-03-26 | 癌化学治療改善剤 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/JP2002/002914 WO2003080075A1 (fr) | 2002-03-26 | 2002-03-26 | Ameliorant pour le traitement chimique du cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003080075A1 true WO2003080075A1 (fr) | 2003-10-02 |
Family
ID=28080696
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/002914 WO2003080075A1 (fr) | 2002-03-26 | 2002-03-26 | Ameliorant pour le traitement chimique du cancer |
Country Status (7)
Country | Link |
---|---|
US (1) | US7462601B2 (ja) |
EP (1) | EP1488796B1 (ja) |
JP (1) | JP4509574B2 (ja) |
AT (1) | ATE493993T1 (ja) |
DE (1) | DE60238874D1 (ja) |
EA (1) | EA009082B1 (ja) |
WO (1) | WO2003080075A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20070260550A1 (en) * | 2006-04-20 | 2007-11-08 | Tobid Pieper | Digital goods export control |
WO2017074211A1 (en) | 2015-10-29 | 2017-05-04 | Dmitry Dmitrievich Genkin | Method to improve safety and efficacy of anti-cancer therapy |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0611152A1 (en) * | 1993-02-10 | 1994-08-17 | Cci Corporation | Novel chromanol glycoside and method for production thereof |
EP0775488A1 (fr) * | 1995-11-23 | 1997-05-28 | Mazal Pharmaceutique | Composition pharmaceutique stable à base d'acide acétylsalicyclique et de tocophérol |
EP0819433A2 (en) * | 1996-07-18 | 1998-01-21 | Cancer Institute (Hospital) Chinese Acadamy Of Medical Sciences | Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin |
JPH1135599A (ja) * | 1997-07-16 | 1999-02-09 | Suetsuna Yoko | 新規なペプチドおよび活性化酸素阻害剤 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH0739000B2 (ja) * | 1987-11-24 | 1995-05-01 | 株式会社明電舎 | 沈澱池の排泥制御装置 |
US5004758A (en) * | 1987-12-01 | 1991-04-02 | Smithkline Beecham Corporation | Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells |
JP3809679B2 (ja) | 1996-01-11 | 2006-08-16 | シーシーアイ株式会社 | クロマノール配糖体およびその製造方法、並びにそれを用いた抗酸化剤 |
JP4027448B2 (ja) | 1996-08-30 | 2007-12-26 | シーシーアイ株式会社 | 放射線防護剤 |
JPH10168095A (ja) * | 1996-12-10 | 1998-06-23 | Cci Corp | 炎症性腸疾患予防および治療剤 |
CN1261803A (zh) * | 1997-07-01 | 2000-08-02 | 埃瑟若詹尼克斯公司 | 抗氧化剂增强对细胞过度增生性疾病的治疗 |
JP3861949B2 (ja) | 1997-07-01 | 2006-12-27 | シーシーアイ株式会社 | クロマノール配糖体およびその製造方法 |
EP1174140B1 (en) * | 1999-03-31 | 2009-11-11 | Cci Corporation | Chromanol glycosides for use in the treatment of dermopathy caused by ultraviolet light |
JP2001261563A (ja) * | 2000-03-16 | 2001-09-26 | Cci Corp | マトリックスメタロプロテアーゼ産生抑制剤 |
-
2002
- 2002-03-26 AT AT02707164T patent/ATE493993T1/de not_active IP Right Cessation
- 2002-03-26 DE DE60238874T patent/DE60238874D1/de not_active Expired - Lifetime
- 2002-03-26 WO PCT/JP2002/002914 patent/WO2003080075A1/ja active Application Filing
- 2002-03-26 US US10/507,760 patent/US7462601B2/en not_active Expired - Lifetime
- 2002-03-26 JP JP2003577901A patent/JP4509574B2/ja not_active Expired - Fee Related
- 2002-03-26 EP EP02707164A patent/EP1488796B1/en not_active Expired - Lifetime
- 2002-03-26 EA EA200400968A patent/EA009082B1/ru not_active IP Right Cessation
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0611152A1 (en) * | 1993-02-10 | 1994-08-17 | Cci Corporation | Novel chromanol glycoside and method for production thereof |
EP0775488A1 (fr) * | 1995-11-23 | 1997-05-28 | Mazal Pharmaceutique | Composition pharmaceutique stable à base d'acide acétylsalicyclique et de tocophérol |
EP0819433A2 (en) * | 1996-07-18 | 1998-01-21 | Cancer Institute (Hospital) Chinese Acadamy Of Medical Sciences | Compositions for increasing the efficacy of cancer drugs with tea catechin and/or theaflavin |
JPH1135599A (ja) * | 1997-07-16 | 1999-02-09 | Suetsuna Yoko | 新規なペプチドおよび活性化酸素阻害剤 |
Also Published As
Publication number | Publication date |
---|---|
EA009082B1 (ru) | 2007-10-26 |
EP1488796A1 (en) | 2004-12-22 |
EP1488796A4 (en) | 2008-02-13 |
EP1488796B1 (en) | 2011-01-05 |
US7462601B2 (en) | 2008-12-09 |
DE60238874D1 (de) | 2011-02-17 |
US20050215492A1 (en) | 2005-09-29 |
EA200400968A1 (ru) | 2005-04-28 |
JP4509574B2 (ja) | 2010-07-21 |
ATE493993T1 (de) | 2011-01-15 |
JPWO2003080075A1 (ja) | 2005-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100675044B1 (ko) | 부작용 경감제 | |
TW201004619A (en) | Methods and compositions for therapeutic treatment | |
CA2659537C (en) | Methods and compositions for promoting activity of anti-cancer therapies | |
KR20090037395A (ko) | 오리도닌을 포함하는 저항성 암의 치료를 위한 조성물 | |
CN111757731A (zh) | 三取代苯并三唑衍生物的使用方法 | |
CN116077631A (zh) | 涉及粘液素的疾病治疗 | |
KR101401220B1 (ko) | 방사선 치료 증강제 | |
AU2004272022A1 (en) | Co-administration of polysaccharide with a chemotherapeutic agent for the treatment of cancer | |
WO2008064425A1 (en) | Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof | |
US6297245B1 (en) | Cisplatin and folic acid administered to treat breast cancer | |
AU2014220455B2 (en) | Sugar-analog phosphorus-containing heterocycles having an anti-metastatic activity | |
RU2415670C2 (ru) | Усиливающий агент для радиационной терапии, включающий производное пиридина в качестве активного ингредиента | |
KR20180117681A (ko) | 글리코알칼로이드 조합 및 그의 다양한 용도 | |
WO2003080075A1 (fr) | Ameliorant pour le traitement chimique du cancer | |
EP1864683B1 (en) | Radiotherapy enhancer | |
EP0563386A1 (en) | Anticancer composition and compound | |
JP2020537689A (ja) | A−ノル−5αアンドロスタン化合物を含む白血球増多製剤およびその使用 | |
EP2902028A1 (en) | Drug composition for treating tumors and application thereof | |
JP4397991B2 (ja) | 抗発癌プロモーター剤 | |
EP1708693B1 (en) | Pharmaceutical compositions containing paltinum complexes with secondary xanthates and therapeutic uses thereof | |
CN1398183A (zh) | 含铂络合物化合物的药物和其用途 | |
JP4825957B2 (ja) | 抗腫瘍剤 | |
JP2554497B2 (ja) | エポキシコハク酸誘導体を含有する医薬組成物 | |
KR20230159375A (ko) | 의약에서 사용하기 위한 4-클로로-n-[2-[(4-클로로페닐)메틸]-3-옥소-1,2,4-티아디아졸-5-일]벤즈아미드 | |
WO1999039719A1 (fr) | Substances preventives et curatives utilisees dans le traitement de troubles lies a la reperfusion d'une zone d'ischemie |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): CA CN GE JP KR UA US UZ |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003577901 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200400968 Country of ref document: EA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10507760 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002707164 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002707164 Country of ref document: EP |